• Blog

COVID-19 Pharma Industry Update from GlobalData

Updated: Jun 30, 2020


30 June


The world of clinical trials is adapting to the "new normal" and companies are bringing trials out of lock down. We're therefore going to stop the daily posts. We'd like to say a huge thank you to our good friends at Global Data for providing such comprehensive information on a daily basis.


Good luck, and stay safe.


23 June


Pipeline Drugs

  • 840 (+10 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 69.3% are in discovery or preclinical

Clinical Trials

  • 2,314 clinical trials globally (+25 from last update)

  • 436 clinical trials with chloroquine or hydroxychloroquine (+1 from last update); 29 have been withdrawn, suspended, or terminated (+2 from last update)

  • 30 clinical trials with remdesivir (+4 from last update)

  • 668 companies and institutions driving prophylactic and curative innovation (-1 from last update)

Deal-making Activity

  • 187 strategic partnerships (+2 from last update)

  • 63 Licensing agreements (unchanged from last update)

  • 9 M&A (unchanged from last update)

  • 28 financing (+1 from last update)

Therapeutic Update Yesterday, Gilead’s CEO Daniel O’Day announced in an open letter to start clinical studies of an inhaled version of remdesivir. After receiving FDA approval, healthy volunteers will be recruited for a Phase I trial set to start in August to investigate remdesivir in earlier stages of COVID-19. Gilead’s antiviral is currently given intravenously, restricting the use to hospital settings. Trials from the company and the NIH showed that remdesivir can reduce the time to clinical recovery significantly from 15 days in the control group to 11 days in the treatment group, and has a less pronounced effect on reducing mortality. O’Day further pointed out that remdesivir is and will be tested in combination with other drugs, for example immune modulators such as baricitinib (Olumiant) and tocilizumab (Actemra). Additionally, Gilead expects to produce more than two million treatment courses by the end of the year and several million doses next year. Ridgeback Therapeutics, which partnered up with Merck in late May, announced the start of two Phase II trials to test its antiviral EIDD-2801 in newly diagnosed COVID-19 patients. In the Phase II studies, the oral ribonucleoside analog will be taken at home or in hospital settings to see if an early treatment can be effective in eliminating the virus; for that purpose Ridgeback already produced hundred thousands of doses. According to the company, a Phase I trial deemed the antiviral as safe in humans, but data has not been published, yet. A preliminary report on the effect of dexamethasone in hospitalized COVID-19 patients has been published on medRxiv, adding more detailed information to last week’s announcement. A total of 2,104 patients received 6mg daily of the corticosteroid dexamethasone for up to ten days and were compared to 4,321 patients in a control group in the randomized trial. Dexamethasone treatment was able to reduce mortality after 28 days by one-third in patients on invasive mechanical ventilation (29.0% vs. 40.7%), by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%), but did show effects in patients that did not receive respiratory support in comparison to the control group (17.0% vs. 13.2%).

Vaccines Update Sanofi’s recombinant COVID-19 vaccine candidate will be ready for clinical trials in September instead of December, according to the company. The vaccine will be based on the same technology used for Sanofi’s seasonal influenza vaccine Flublok with the addition of GSK’s pandemic adjuvant. Furthermore, Sanofi is expanding its partnership and licensing agreement with Translate Bio, which is developing a mRNA vaccine for COVID-19. The Massachusetts-based company will receive $425M from Sanofi and further payments up to $1.9B for the development and potential global roll-out of vaccines based on Translate Bio’s mRNA platform. Clinical trials for the mRNA vaccine candidate are set to start in Q4 2020. Drug maker Chongqing Zhifei Biological Products is the next Chinese company to start clinical studies of its COVID-19 vaccine candidate. Co-developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine candidate received regulatory approval from Chinese authorities to start Phase I trials.

Disrupted clinical trials

  • 1,210 disrupted clinical trials (-6 from last update)

  • 972 organizations (industry and academia) are impacted (-1 from last update)

  • 578 companies are impacted (unchanged from last update) as sponsor, collaborator or CRO

  • 1,308 drugs involved (-7 from last update)

  • Majority of delays are oncology and CNS with 29.3% and 17.9%, respectively

  • 30.6% of trials are in Phase III, III/IV or IV

  • 312 clinical trials resumed after disruption (+11 from last update



22 June


Pipeline Drugs

  • 830 (+18 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70% are in discovery or preclinical

Clinical Trials

  • 2,289 clinical trials globally (+39 from last update)

  • 435 clinical trials with chloroquine or hydroxychloroquine (+9 from last update); 27 have been withdrawn, suspended, or terminated

  • 26 clinical trials with remdesivir (+3 from last update)

  • 669 companies and institutions driving prophylactic and curative innovation (+8 from last update)

Deal-making Activity

  • 185 strategic partnerships (unchanged from last update)

  • 63 Licensing agreements (unchanged from last update)

  • 9 M&A (unchanged from last update)

  • 27 financing (unchanged from last update)

Therapeutic Update The NIH stopped its hydroxychloroquine ORCHID study that was investigating the safety and effectiveness of the antimalarial drug in hospitalized COVID-19 patients. The data and safety monitoring board decided a benefit will be unlikely after reviewing data from 470 patients of the placebo-controlled trial that started in April. Also Novartis stopped its hydroxychloroquine study that had the goal to enroll 440 participants, but faced problems recruiting enough participants. Over the past weeks, multiple larger studies showed no benefit of chloroquine and hydroxychloroquine treatment for COVID-19 patients, with or without antibiotics, the WHO discontinued clinical trials with the drug, and the FDA revoked its Emergency Use Authorization for the use in COVID-19 patients. In India, Hetero Labs and Cipla received regulatory approval for the manufacturing of a generic version of Gilead’s remdesivir. The antiviral will be marketed under the brand name Covifor by Hetero and Cipremi by Cipla, and will be priced at $66-$79 for a 100mg dose, resulting in a cost of $330-$395 for a 5-day treatment course. An earlier clinical trial from Gilead showed a 5-day treatment course to be as effective as a 10-day treatment course. Gilead licensed remdesivir to several generic drug makers in India and Pakistan for the manufacturing and distribution in 127 low-and middle income countries in early May.

Vaccines Update After CanSino, Sinopharm, and Sinovac, another Chinese developer's COVID-19 vaccine candidate will enter Phase II studies. The inactivated vaccine developed by the Institute of Medical Biology at the Chinese Academy of Medical Sciences (IMBCAMS) has an ongoing Phase I trial with 200 participants, and the Phase II study has the goal of determining the optimal dose and observing antibody responses.

Disrupted clinical trials

  • 1,216 disrupted clinical trials (+4 from last update)

  • 973 organizations (industry and academia) are impacted (+6 from last update)

  • 578 companies are impacted (+5 from last update) as sponsor, collaborator or CRO

  • 1,315 drugs involved (+7 from last update)

  • Majority of delays are oncology and CNS with 29.4% and 17.8%, respectively

  • 30.4% of trials are in Phase III, III/IV or IV

  • 301 clinical trials resumed after disruption (+5 from last update)



19 June


Pipeline Drugs

  • 812 (unchanged from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70.3% are in discovery or preclinical

Clinical Trials

  • 2,250 clinical trials globally (+2 from last update)

  • 426 clinical trials with chloroquine or hydroxychloroquine (unchanged from last update)

  • 23 clinical trials with remdesivir (unchanged from last update)

  • 661 companies and institutions driving prophylactic and curative innovation (+7 from last update)

Deal-making Activity

  • 185 strategic partnerships (unchanged from last update)

  • 63 Licensing agreements (unchanged from last update)

  • 9 M&A (unchanged from last update)

  • 27 financing (unchanged from last update)

Therapeutic Update Humanigen, a biotech company based in California, published positive COVID-19 data from their antibody lenzilumab on the preprint server medRxiv. The drug is in development to treat several types of lymphoma. In 12 patients with severe and critical COVID-19 pneumonia, 11 showed clinical improvement after treatment with lenzilumab with a median discharge time of five days. The improvement is thought to be associated with the drug's neutralization of granulocyte macrophage-colony stimulating factors that correlate with the body's strong immune response, but larger and randomized trials have to confirm the positive results.

Vaccines Update Clover Biopharmaceuticals is the next Chinese company to start clinical studies of a COVID-19 vaccine. The Phase I study will enroll 150 adult and elderly subjects in Australia to test the company’s candidate SCB-2019, a recombinant protein vaccine based on the trimer-tag technology. The vaccine will utilize either an adjuvant from GSK or Dynavax, both versions will be tested in the trial. A Phase II/III study is planned to start later in 2020.

Disrupted clinical trials

  • 1,212 disrupted clinical trials (-22 from last update)

  • 967 organizations (industry and academia) are impacted (-3 from last update)

  • 573 companies are impacted (unchanged from last update) as sponsor, collaborator or CRO

  • 1,308 drugs involved (-6 from last update)

  • Majority of delays are oncology and CNS with 29.2% and 17.8%, respectively

  • 30.7% of trials are in Phase III, III/IV or IV

  • 296 clinical trials resumed after disruption (+23 from last update)



18 June


Pipeline Drugs

  • 812 (+12 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70.3% are in discovery or preclinical

Clinical Trials

  • 2,248 clinical trials globally (+28 from last update)

  • 426 clinical trials with chloroquine or hydroxychloroquine (+4 from last update)

  • 23 clinical trials with remdesivir (unchanged from last update)

  • 654 companies and institutions driving prophylactic and curative innovation (+3 from last update)

Deal-making Activity

  • 185 strategic partnerships (+1 from last update)

  • 63 Licensing agreements (unchanged from last update)

  • 9 M&A (unchanged from last update)

  • 27 financing (unchanged from last update)

Therapeutic Update The WHO decided to stop investigating hydroxychloroquine in its Solidarity trial after reviewing available data for the anti-malarial drug, showing no benefits as compared to standard treatment. The Solidarity study started out with four treatment options for COVID-19 at the end of March and will continue investigating remdesivir, the HIV drug combo lopinavir/ritonavir, and the multiple sclerosis treatment interferon-1a. After dropping the Emergency Use Authorization of chloroquine and hydroxychloroquine for the treatment of COVID-19, the FDA now warns against potential drug interactions between the antimalarial and Gilead’s remdesivir. Non-clinical studies in human cell culture showed that chloroquine potentially reduces the antiviral activity of remdesivir. Gilead meanwhile is planning to start a Phase II/III clinical study testing its antiviral remdesivir in pediatric patients with severe COVD19. Although children are less affected by COVID-19, younger patients with underlying health conditions are at risk. A total of 50 pediatric patients will be enrolled at trial sites in the US and Europe. Roche’s rheumatoid arthritis IL-6 inhibitor Actemra (tocilizumab) showed disappointing results in an Italian study in patients with early-stage COVID-19 pneumonia. The trial with 126 participants was stopped early, as Actemra was not able to reduce severe respiratory symptoms, intensive care visits, or deaths, as compared to standard treatment. Also Sanofi/Regeneron’s IL-6 inhibitor Kevzara (sarilumab) showed no benefits in severe COVID-19 patients in April, but studies are continuing in critical COVID-19 patients.

Vaccines Update The European Union is in negotiations with Johnson & Johnson for the advance purchase of its COVID-19 vaccine candidate. The deal will be covered by the emergency fund the EU set aside to supply COVID-19 vaccines to its citizens, and will likely include candidates developed by other companies. AstraZeneca signed a deal with Cobra Biologics for the manufacturing of its COVID-19 vaccine candidate. The company has manufacturing facilities in the UK, Sweden, and the US, where it will produce the adenovirus vector-based vaccine developed by Oxford University.

Disrupted clinical trials

  • 1,234 disrupted clinical trials (-13 from last update)

  • 970 organizations (industry and academia) are impacted (-16 from last update)

  • 573 companies are impacted (-7 from last update) as sponsor, collaborator or CRO

  • 1,314 drugs involved (-24 from last update)

  • Majority of delays are oncology and CNS with 29.3% and 17.9%, respectively

  • 30.6% of trials are in Phase III, III/IV or IV

  • 273 clinical trials resumed after disruption (+15 from last update)


17 June 2020

The eruption of the COVID-19 pandemic has propelled the pharmaceutical industry into action, with a race to develop both preventive and therapeutic interventions. The pipeline is crowded with clinical investigations of novel and existing drugs growing exponentially. Gilead's remdesivir is the new standard of care in the US and has Emergency Use Authorization in the US and in South Korea. The drug is also approved in Japan and India for treatment in hospitalized patients and received conditional approval in Singapore on June 10 for COVID-19 patients with oxygen saturation less than or equal to 94% and those that require supplemental oxygen or intensive breathing support, including invasive mechanical ventilation. The European Medicines Agency (EMA) also recently announced that the organization was reviewing remdesivir’s application for conditional authorization in the EU. Pipeline Drugs

  • 800 (+5 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70.1% are in discovery or preclinical

Clinical Trials

  • 2,220 clinical trials globally (+16 from last update)

  • 422 clinical trials with chloroquine or hydroxychloroquine (unchanged from last update)

  • 23 clinical trials with remdesivir (+1 from last update)

  • 651 companies and institutions driving prophylactic and curative innovation (+7 from last update)

Deal-making Activity

  • 184 strategic partnerships (unchanged from last update)

  • 63 Licensing agreements (unchanged from last update)

  • 9 M&A (unchanged from last update)

  • 27 financing (unchanged from last update)

Therapeutic Update Following the positive, preliminary results from the dexamethasone study announced yesterday, the United Kingdom approved the use of the corticosteroid in severe COVID-19 patients. Dexamethasone was shown to reduce mortality by 35% in hospitalized COVID-19 patients on mechanical ventilation, and by 20% in patients on supplemental oxygen support. The UK government also wants to make sure the drug will be available by increasing its stock and by restricting its export. With Dr. Reddy’s Laboratories, Gilead is adding another company to the list of drug makers that receive a license for the manufacturing and production of its antiviral remdesivir in low-and middle income countries, including India. Remdesivir has Emergency Use Authorization for the treatment of COVID-19 patients in the US and South Korea, and is approved for the use in severe COVID-19 patients in Japan, India, and Singapore. Regeneron received $85M in funding from BARDA for the development of its antibody cocktail for COVID-19. The US agency previously supported Regeneron’s Ebola antibody treatment development, with Regeneron starting clinical trials of its antibody cocktail for COVID-19 last week.

Vaccines Update Operation Warp Speed’s final list will include two more COVID-19 vaccine candidates, in addition to the five already chosen. The US government’s initiative to fund the development and production of up to 300 million vaccine doses until early next year shortlisted AstraZeneca, Johnson & Johnson, Merck, Moderna, and Pfizer’s candidates earlier this month. Trump administration officials furthermore promised to make successful COVID-19 vaccines available for free to people who cannot afford it, and said health insurance providers are considering to provide the vaccine for free to its subscribers. When a vaccine becomes available, it would be provided first to the high-risk population and frontline healthcare workers, they added. Sinopharm Group announced preliminary results from a Phase I/II study of the inactivated COVID-19 vaccine candidate its subsidiary Wuhan Institute of Biological Products is developing. A total of 1,120 participants were enrolled and received two shots of one of three different vaccine doses, given at three different intervals, or a placebo. A seroconversion rate of 97.6% was reported for the 14- and 21-day interval, and 100% for the 28-day interval for the middle dose. These are promising results, however, it is unclear, yet, if neutralizing antibodies are sufficient to both protect severe COVID-19 infections and prevent further spread of the virus. German biotech CureVac will start Phase I clinical trials with 168 patients for its mRNA COVID-19 vaccine candidate, after receiving approval from German and Belgian authorities. This news comes two days after the German government announced to support the vaccine development effort with $300M and receiving a considerable stake in the company.

Disrupted clinical trials

  • 1,247 disrupted clinical trials (-5 from last update)

  • 986 organizations (industry and academia) are impacted (-5 from last update)

  • 580 companies are impacted (-4 from last update) as sponsor, collaborator or CRO

  • 1,338 drugs involved (-6 from last update)

  • Majority of delays are oncology and CNS with 29.4% and 17.8% respectively

  • 30.4% of trials are in Phase III, III/IV or IV

  • 258 clinical trials resumed after disruption (+9 from last update)




16 June


Pipeline Drugs

  • 795 (+9 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70.3% are in discovery or preclinical

Clinical Trials

  • 2,204 clinical trials globally (+13 from last update)

  • 422 clinical trials with chloroquine or hydroxychloroquine (unchanged from last update)

  • 22 clinical trials with remdesivir (unchanged from last update)

  • 644 companies and institutions driving prophylactic and curative innovation (+9 from last update)

Deal-making Activity

  • 184 strategic partnerships (+1 from last update)

  • 63 Licensing agreements (+2 from last update)

  • 9 M&A (unchanged from last update)

  • 27 financing (unchanged from last update)

Therapeutic Update Preliminary results from the UK-led RECOVERY clinical study showed that the corticosteroid dexamethasone reduces 28-day mortality in severe hospitalized COVID-19 patients on mechanical ventilation by 35% and in patients receiving oxygen support by 20%. No benefit of dexamethasone treatment was observed in COVID-19 patients who did not require respiratory support. In the randomized study, 2,014 participants who received a low dose of 6mg dexamethasone once daily were compared with 4,321 patients on standard care. The RECOVERY study investigates several marketed drugs for the treatment of COVID-19, such as antivirals, immune modulators, and also could not show a benefit from the use of hydroxychloroquine treatment in COVID-19 patients two weeks ago. These results are very promising for severe COVID-19 patients on oxygen support; however, the complete data are not yet available and not published, so these results should be approached keeping this in mind.

Vaccines Update AstraZeneca reached a deal with the drug and drug delivery technology provider Catalent for vial filling and packaging of “hundreds of millions of doses” of AstraZeneca/Oxford University’s COVID-19 vaccine candidate AZD1222 in Catalent’s manufacturing facility in Anagni, Italy, from August 2020 through early 2020. AstraZeneca made several deals with EU member states, the US, the UK, CEPI, and Gavi the Vaccine Alliance for up to one billion doses in total, and furthermore licensed its vaccine to the Serum Institute of India for the production and distribution of one billion doses in low-and middle-income countries. Sanofi is preparing for the production of its two COVID-19 vaccine candidates by investing $680M in a vaccine production facility and a new vaccine research center in France. Sanofi has two COVID-19 vaccines in preclinical development: a recombinant vaccine based on technology that is utilized in producing the seasonal influenza vaccine Flublok which will use GSK’s adjuvant system, and an mRNA vaccine candidate that is being developed in collaboration with Massachusetts-based biotech TranslateBio. The self-amplifying mRNA COVID-19 vaccine candidate being developed at the Imperial College London is entering Phase I trials this week. The vaccine's development is being funded with $56M from the UK government, and Phase I will include 300 participants who will receive two doses of the vaccine. If successful, the vaccine will be produced by the newly founded company VacEquity Global Health in partnership with Morningside Ventures, an investment company from Hong Kong, and will be available at a low-cost for low-and middle-income countries.

Disrupted clinical trials

  • 1,252 disrupted clinical trials (+6 from last update)

  • 991 organizations (industry and academia) are impacted (+2 from last update)

  • 584 companies are impacted (+2 from last update) as sponsor, collaborator or CRO

  • 1,344 drugs involved (+5 from last update)

  • Majority of delays are oncology and CNS with 29.5% and 17.8% respectively

  • 30.4% of trials are in Phase III, III/IV or IV

249 clinical trials resumed after disruption (unchanged from last update)


15 June


The eruption of the COVID-19 pandemic has propelled the pharmaceutical industry into action, with a race to develop both preventive and therapeutic interventions. No options are currently available in either category but the pipeline is crowded with clinical investigations of novel and existing drugs growing exponentially. Gilead's remdesivir is the new standard of care in the US and has Emergency Use Authorization in the US and in South Korea. The drug is also approved in Japan and India for treatment in hospitalized patients and received conditional approval in Singapore on June 10 for COVID-19 patients with oxygen saturation less than or equal to 94% and those that require supplemental oxygen or intensive breathing support, including invasive mechanical ventilation. The European Medicines Agency (EMA) also recently announced that the organization was reviewing remdesivir’s application for conditional authorization in the EU. Pipeline Drugs

  • 786 (+9 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70.1% are in discovery or preclinical

Clinical Trials

  • 2,191 clinical trials globally (+22 from last update)

  • 422 clinical trials with chloroquine or hydroxychloroquine (+4 from last update)

  • 22 clinical trials with remdesivir (unchanged from last update)

  • 635 companies and institutions driving prophylactic and curative innovation (+7 from last update)

Deal-making Activity

  • 183 strategic partnerships (+2 from last update)

  • 61 Licensing agreements (+4 from last update)

  • 9 M&A (unchanged from last update)

  • 27 financing (unchanged from last update)

Therapeutic Update The FDA has withdrawn the Emergency Use Authorization for the antimalarial drugs chloroquine and hydroxychloroquine. The agency said it “determined that CQ and HCQ are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA”, especially considering various serious adverse effects, such as cardiovascular problems, that have been reported in recent studies. Accumulating evidence from studies using chloroquine / hydroxychloroquine with or without antibiotics showed no benefits compared to placebo-control groups, but in addition to serious adverse effects also an increase in mortality. However, it has to be seen if this will bring an end to the discussion around the antimalarial drug, especially given that there are more than 350 ongoing and planned clinical studies testing the drug for the treatment of COVID-19. Today, Eli Lilly announced the start of a Phase III clinical trial to test its JAK1/JAK2 inhibitor baricitinib in hospitalized COVID-19 patients. Baricitinib, marketed as Olumiant for the treatment of rheumatoid arthritis, may reduce the human body’s immune system overreaction in response to the viral infection. The placebo-controlled study with 400 COVID-19 patients will assess baricitinib’s effect on improving oxygen support. Other rheumatoid arthritis drugs that suppress the immune system are already in clinical trials, such as Roche’s Actrema (tocilizumab) and Regeneron/Sanofi’s Kevzara (sarilumab). Baricitinib was identified as a potential treatment for COVID-19 with both anti-viral and anti-cytokine properties using BenevolentAI’s proprietary AI drug discovery and development platform.

Vaccines Update Preliminary data from Chinese biotech Sinovac, published on Saturday, showed promising results from the Phase I/II of its inactivated COVID-19 vaccine candidate CoronaVac. A total of 743 healthy subjects have been enrolled in the randomized, placebo-controlled study, of which 143 are in Phase I and 600 in Phase II. The vaccine induced neutralizing antibodies 14 days after vaccination with a seroconversion rate of 90%, and no severe adverse events have been reported. Sinovac is preparing to submit a Phase III study protocol to Chinese authorities in the coming weeks and start clinical trials in Brazil in collaboration with the Instituto Butantan. The public institute Butantan is one of the biggest vaccine manufacturers in Latin America. AstraZeneca entered another deal for the production of its COVID-19 vaccine candidate AZD1222, developed by Oxford University, this time with Europe’s Inclusive Vaccines Alliance (IVA) for the supply of 400 million vaccine doses by the end of 2020. The Alliance, led by France, Germany, Italy, and the Netherlands, was formed to speed up the development and production of COVID-19 vaccines in Europe and as a response to vaccine efforts in the US and China. AstraZeneca previously entered deals with the US, the UK, CEPI, and Gavi the Vaccine Alliance, and licensed its vaccine to the Serum Institute of India. German biotech CureVac is receiving up to $300M from the German Ministry of Economy and Energy for the development of its mRNA vaccine candidate for COVID-19. This deal is part of Germany’s effort to gain more independence in drug manufacturing. CureVac is planning to start Phase I/II clinical trials for its mRNA vaccine candidate by the end of June.

Disrupted clinical trials

  • 1,246 disrupted clinical trials (unchanged from last update)

  • 989 organizations (industry and academia) are impacted (+10 from last update)

  • 582 companies are impacted (+5 from last update) as sponsor, collaborator or CRO

  • 1,339 drugs involved (-3 from last update)

  • Majority of delays are oncology and CNS with 29.6% and 17.9% respectively

  • 30.4% of trials are in Phase III, III/IV or IV

  • 249 clinical trials resumed after disruption (+6 from last update)


12 June


The eruption of the COVID-19 pandemic has propelled the pharmaceutical industry into action, with a race to develop both preventive and therapeutic interventions. No options are currently available in either category but the pipeline is crowded with clinical investigations of novel and existing drugs growing exponentially. Gilead’s remdesivir is the new standard of care in the US and has Emergency Use Authorization in the US and in South Korea. The drug is also approved in Japan and India for treatment in hospitalized patients and received conditional approval in Singapore on June 10 for COVID-19 patients with oxygen saturation less than or equal to 94% and those that require supplemental oxygen or intensive breathing support, including invasive mechanical ventilation. Pipeline Drugs

  • 777 (+12 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70.4% are in discovery or preclinical

Clinical Trials

  • 2,169 clinical trials globally (+34 from last update)

  • 418 clinical trials with chloroquine or hydroxychloroquine (+2 from last update)

  • 22 clinical trials with remdesivir (unchanged from last update)

  • 628 companies and institutions driving prophylactic and curative innovation (+8 from last update)

Deal-making Activity

  • 181 strategic partnerships (+1 from last update)

  • 57 Licensing agreements (unchanged from last update)

  • 9 M&A (unchanged from last update)

  • 27 financing (+1 from last update)

Therapeutic Update Regeneron announced yesterday the start of clinical trials for its dual antibody cocktail REGN-COV2 for COVID-19. By studying four groups of subjects - hospitalized and non-hospitalized COVID-19 patients, as well as uninfected people in different high-exposure settings - the antibody’s ability as a therapeutic and prophylactic for COVID-19 infections will be tested. The antibodies are being developed using the proprietary VelociSuite technology that has been used successfully in developing an antibody cocktail for the treatment of Ebola, currently awaiting FDA approval. Eli Lilly and its partners AbCellera and Junshi Biosciences brought antibodies to the clinic earlier this month; other prominent companies with neutralizing antibodies in development for the treatment and prevention of COVID-19 include Amgen, AstraZeneca, AbbVie, and GlaxoSmithKline.

Vaccines Update With more than 120 COVID-19 vaccine candidates in development and 10 in clinical studies, the logistics of producing hundreds of millions to billions of doses of a vaccine is daunting. Not only raw material for the vaccine is needed, but also manufacturing sites, including production and testing equipment, have to be scaled up accordingly. Moderna’s CEO Stéphane Bancel and Merck’s vaccine president John Markels said during the BIO conference, they are worried about both the supply chain and hiring enough qualified people to help in the effort to scale up the production of so many vaccine doses. In order to prepare for the manufacturing and distribution of a successful COVID-19 vaccine, the US national stockpile is planning to store 400 million syringes and needles by December and up to 700 million by early next year. Not only drugs and drug precursors have been in shortage during the ongoing pandemic, but also personal protective equipment and material for testing kits. Now, also soda bottle manufacturers who usually work with Coca-Cola have stepped up to produce test tubes that are used in COVID-19 testing kits. Sinopharm Group, one of the five developers of COVID-19 vaccines in China, published positive results from animal studies of its inactivated vaccine candidate BBIBP-CorV in ‘Cell’. Two 2μg doses of the vaccine candidate induced high levels of neutralizing antibody titers in mice, rats, guinea pigs, rabbits, and nonhuman primates. BBIBP-CorV is already in Phase I/II clinical trials in China. Other companies developing COVID-19 vaccines in China include CanSino with their adenovirus vector-based vaccine in Phase II, and Sinovac with another inactivated vaccine candidate. Contract drug manufacturer and vaccine developer Emergent BioSolutions agreed on an $85M deal with AstraZeneca for the US supply of the Oxford University/AstraZeneca vaccine candidate AZD122. Earlier this month, Emergent signed a $628M deal with BARDA for the production of up to several hundred million COVID-19 vaccine doses for the US, and AstraZeneca made deals with CEPI, Gavi, and the Serum Institute for large-scale distribution and production of its vaccine candidate. Yesterday, Moderna published data from an animal study of their COVID-19 vaccine mRNA-1273 on the non-peer reviewed preprint server BioRxiv. They showed that "mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology". Moderna's vaccine candidate is currently in Phase II. After FDA review, the Phase III study protocol is finalized with the goal to test the 100μg dose of mRNA-1273 in 30,000 participants starting in July.

Disrupted clinical trials

  • 1,246 disrupted clinical trials (-6 from last update)

  • 979 organizations (industry and academia) are impacted (+1 from last update)

  • 577 companies are impacted (+3 from last update) as sponsor, collaborator or CRO

  • 1,342 drugs involved (-10 from last update)

  • Majority of delays are oncology and CNS with 29.8% and 17.7% respectively

  • 30.3% of trials are in Phase III, III/IV or IV

  • 243 clinical trials resumed after disruption (+21 from last update)


11 June


Pipeline Drugs

  • 765 (+7 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70% are in discovery or preclinical

Clinical Trials

  • 2,135 clinical trials globally (+7 from last update)

  • 416 clinical trials with chloroquine or hydroxychloroquine (+2 from last update)

  • 22 clinical trials with remdesivir (unchanged from last update)

  • 620 companies and institutions driving prophylactic and curative innovation (+5 from last update)

Deal-making Activity

  • 180 strategic partnerships (+4 from last update)

  • 57 Licensing agreements (+4 from last update)

  • 9 M&A (unchanged from last update)

  • 26 financing (unchanged from last update)

Vaccines Update Johnson & Johnson announced yesterday to start Phase I/II clinical trials of its COVID-19 vaccine candidate in the second half of July, two months earlier than initially planned. Promising results in preclinical studies and accelerated regulatory decisions led to the faster timeline. Ad26.COV2-S, recombinant is developed by J&J's pharmaceutical arm Janssen and utilizes the proprietary AdVac adenovirus vector and the PER.C6 cell line. For the randomized, double-blind, and placebo-controlled Phase I/II studies, 1,045 healthy adults in the US and Belgium will be enrolled. According to NIH officials talking to the Wall Street Journal, the NIH is planning large Phase III studies with COVID-19 vaccine candidates from Moderna, AstraZeneca, and Johnson & Johnson in the coming months. Moderna's mRNA-based vaccine is currently in Phase II, and Phase III is on track to start in July. AstraZeneca/Oxford University's adenovirus vector-based vaccine AZD1222 is in Phase II as well, and Phase III studies are planned for August. With J&J's vaccine entering Phase I/II only in July, it has to be seen if the Phase III September timeline is feasible.

Disrupted clinical trials

  • 1,252 disrupted clinical trials (-1 from last update)

  • 978 organizations (industry and academia) are impacted (unchanged from last update)

  • 574 companies are impacted (unchanged from last update) as sponsor, collaborator or CRO

  • 1,352 drugs involved (-1 from last update)

  • Majority of delays are oncology and CNS with 30% and 17.7% respectively

  • 30.4% of trials are in Phase III, III/IV or IV

  • 222 clinical trials resumed after disruption (+1 from last update)



10 June


Pipeline Drugs

  • 758 (+6 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 69.8% are in discovery or preclinical

Clinical Trials

  • 2,128 clinical trials globally (+28 from last update)

  • 414 clinical trials with chloroquine or hydroxychloroquine (+4 from last update)

  • 22 clinical trials with remdesivir (unchanged from last update)

  • 615 companies and institutions driving prophylactic and curative innovation (+5 from last update)

Deal-making Activity

  • 176 strategic partnerships (+2 from last update)

  • 53 Licensing agreements (+1 from last update)

  • 9 M&A (unchanged from last update)

  • 26 financing (unchanged from last update)

Therapeutic Update With AstraZeneca, another big pharma company entered the development of antibody therapies for the treatment of COVID-19. The company licensed six coronavirus-neutralizing antibodies from Vanderbilt University in Tennessee, and will bring two of them as a cocktail into clinical trials by August. AstraZeneca signed agreements with the US agencies DARPA and BARDA to support a Phase I trial and for manufacturing of the antibodies for the clinical studies.

Vaccines Update Although COVID-19 vaccines are early in development, discussions about pricing have already started. Pfizer's CEO Albert Bourla said yesterday in an interview, the mRNA vaccine his company is developing in collaboration with BioNTech won't have a "huge price" and the company won't take advantage of the situation. Similar comments were made by Moderna officials, while AstraZeneca made deals with CEPI and the Vaccine Alliance Gavi to ensure equitable access to vaccines in low-and middle-income countries.

Disrupted clinical trials

  • 1,253 disrupted clinical trials (-10 from last update)

  • 978 organizations (industry and academia) are impacted (+2 from last update)

  • 574 companies are impacted (unchanged from last update) as sponsor, collaborator or CRO

  • 1,353 drugs involved (-12 from last update)

  • Majority of delays are oncology and CNS with 30.1% and 17.6% respectively

  • 30.4% of trials are in Phase III, III/IV or IV

  • 221 clinical trials resumed after disruption (+17 from last update)


9 June


Pipeline Drugs

  • 752 (+5 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 69.8% are in discovery or preclinical

Clinical Trials

  • 2,100 clinical trials globally (+22 from last update)